FR2825716B1 - Nouveaux polynucleotides et polypeptides de l'ifn alpha 7 - Google Patents

Nouveaux polynucleotides et polypeptides de l'ifn alpha 7

Info

Publication number
FR2825716B1
FR2825716B1 FR0107588A FR0107588A FR2825716B1 FR 2825716 B1 FR2825716 B1 FR 2825716B1 FR 0107588 A FR0107588 A FR 0107588A FR 0107588 A FR0107588 A FR 0107588A FR 2825716 B1 FR2825716 B1 FR 2825716B1
Authority
FR
France
Prior art keywords
polypeptides
ifn alpha
novel polynucleotides
polynucleotides
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0107588A
Other languages
English (en)
French (fr)
Other versions
FR2825716A1 (fr
Inventor
Jean Louis Escary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GenOdyssee SA
Original Assignee
GenOdyssee SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GenOdyssee SA filed Critical GenOdyssee SA
Priority to FR0107588A priority Critical patent/FR2825716B1/fr
Priority to AU2002317867A priority patent/AU2002317867A1/en
Priority to EP02747458A priority patent/EP1395684A2/en
Priority to JP2003503798A priority patent/JP2005500029A/ja
Priority to PCT/EP2002/007456 priority patent/WO2002101048A2/en
Publication of FR2825716A1 publication Critical patent/FR2825716A1/fr
Priority to US10/732,485 priority patent/US7399464B2/en
Application granted granted Critical
Publication of FR2825716B1 publication Critical patent/FR2825716B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
FR0107588A 2001-06-11 2001-06-11 Nouveaux polynucleotides et polypeptides de l'ifn alpha 7 Expired - Fee Related FR2825716B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0107588A FR2825716B1 (fr) 2001-06-11 2001-06-11 Nouveaux polynucleotides et polypeptides de l'ifn alpha 7
AU2002317867A AU2002317867A1 (en) 2001-06-11 2002-06-11 New polynucleotides and polypeptides of the ifnalpha-7 gene
EP02747458A EP1395684A2 (en) 2001-06-11 2002-06-11 New polynucleotides and polypeptides of the ifnalpha-7 gene
JP2003503798A JP2005500029A (ja) 2001-06-11 2002-06-11 IFNα−7遺伝子の新規ポリヌクレオチド及びポリペプチド
PCT/EP2002/007456 WO2002101048A2 (en) 2001-06-11 2002-06-11 NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-7 GENE
US10/732,485 US7399464B2 (en) 2001-06-11 2003-12-11 Polypeptides of the IFNα-7 gene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0107588A FR2825716B1 (fr) 2001-06-11 2001-06-11 Nouveaux polynucleotides et polypeptides de l'ifn alpha 7

Publications (2)

Publication Number Publication Date
FR2825716A1 FR2825716A1 (fr) 2002-12-13
FR2825716B1 true FR2825716B1 (fr) 2004-09-24

Family

ID=8864156

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0107588A Expired - Fee Related FR2825716B1 (fr) 2001-06-11 2001-06-11 Nouveaux polynucleotides et polypeptides de l'ifn alpha 7

Country Status (6)

Country Link
US (1) US7399464B2 (cg-RX-API-DMAC7.html)
EP (1) EP1395684A2 (cg-RX-API-DMAC7.html)
JP (1) JP2005500029A (cg-RX-API-DMAC7.html)
AU (1) AU2002317867A1 (cg-RX-API-DMAC7.html)
FR (1) FR2825716B1 (cg-RX-API-DMAC7.html)
WO (1) WO2002101048A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FR2822845B1 (fr) * 2001-03-30 2003-12-12 Genodyssee Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP7611820B2 (ja) 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Dll3シングルドメイン抗体およびその治療用組成物
AU2019356573B2 (en) 2018-10-11 2025-12-18 Inhibrx Biosciences, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
CN113166261A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 B7h3单域抗体及其治疗性组合物
US12590169B2 (en) 2018-10-11 2026-03-31 Inhibrx Biosciences, Inc. 5T4 single domain antibodies and therapeutic compositions thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA814375B (en) 1980-07-01 1982-07-28 Hoffmann La Roche Interferons and process for their preparation
CH651308A5 (de) 1980-07-01 1985-09-13 Hoffmann La Roche Interferone und deren herstellung.
JPH064673B2 (ja) 1980-11-10 1994-01-19 ゲネンテツク・インコ−ポレ−テツド ハイブリド型ヒト白血球インタフエロン
US4810645A (en) * 1981-08-14 1989-03-07 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L
EP0072541A3 (en) 1981-08-14 1984-04-18 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Human leukocyte interferons, process for their microbial production, intermediates therefor and compositions containing them
US4801685A (en) * 1981-08-14 1989-01-31 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L
US4678751A (en) * 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
GB2108510B (en) 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof
WO1983002460A1 (en) 1982-01-15 1983-07-21 Cetus Corp Interferon-alpha 74
US5098703A (en) 1982-01-15 1992-03-24 Cetus Corporation Interferon-alpha 76
IE54592B1 (en) 1982-03-08 1989-12-06 Genentech Inc Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby
CA1217440A (en) 1982-08-18 1987-02-03 Michael A. Innis INTERFERON .alpha. 6L
IL71555A (en) 1984-04-15 1992-06-21 State Of Israel Israel Inst Fo Bovine interferon
SE8502430L (sv) 1985-05-15 1986-11-16 Kabivitrum Ab En cdna-molekyl som kodar for expressionen av en polypeptid av typen interferon alfa, en bakteriell eller celluler verd transformerad med en sadan molekyl och en polypeptid som uppvisar interferonaktivetet framstelld me
SU1703690A1 (ru) 1986-04-30 1992-01-07 Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Рекомбинантна плазмидна ДНК @ 22, кодирующа синтез интерферона @ -11 человека, и штамм бактерии РSеUDомоNаS Sp. -продуцент- интерферона @ -11 человека
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
US6001589A (en) * 1993-06-11 1999-12-14 Pbl Biomedical Laboratories, Inc. Method of identifying proteins modified by disease states related thereto
US5789551A (en) * 1993-06-11 1998-08-04 Pestka Biomedical Laboratories, Inc. Human leukocyte interferon Hu-IFN-α001
WO2000039280A2 (en) * 1998-12-31 2000-07-06 Viragen, Inc. Leukocyte-derived interferon preparations
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
AU8001300A (en) * 1999-10-07 2001-05-10 Maxygen, Inc. Ifn-alpha homologues
EP1355939A2 (en) * 2000-11-03 2003-10-29 Pestka Biomedical Laboratories, Inc. Interferons, uses and compositions related thereto
JPWO2002069913A1 (ja) 2001-03-01 2004-09-09 株式会社クリニカルコスメティック 皮膚改善用組成物セット

Also Published As

Publication number Publication date
WO2002101048A3 (en) 2003-08-14
FR2825716A1 (fr) 2002-12-13
AU2002317867A1 (en) 2002-12-23
JP2005500029A (ja) 2005-01-06
EP1395684A2 (en) 2004-03-10
WO2002101048A2 (en) 2002-12-19
US20040126799A1 (en) 2004-07-01
US7399464B2 (en) 2008-07-15

Similar Documents

Publication Publication Date Title
NO20040246L (no) TACI'er- og BR3-polypeptider og anvendelser derav
FR2823220B1 (fr) Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
EP1401476A4 (en) IGF-ANTAGONISTS PEPTIDES
IS1988B (is) Interferon tengd efni
EE200100080A (et) C-hepatiidi inhibiitorpeptiidid
EP1453557A4 (en) IMPROVED STENT COVER
EP1143001A4 (en) INTERFERON ALPHA
EP1466979A4 (en) LYSYL OXIDASES MUSHROOM ORIGIN
NO20002691D0 (no) IFNAR 2/IFN kompleks
FR2797298B1 (fr) Volume d'echappement
EP0977482A4 (en) IDENTIFICATION OF POLYNUCLEOTIDS THAT ENCODE NEW HELIOBACTER POLYPEPTIDES IN THE HELIOBACTER GENOM
FR2825102B1 (fr) Nouveaux polynucleotides et polypeptides de l'interferon alpha 14
IL153568A (en) Novel polypeptides and polynucleotides
EP1409661A4 (en) HDAC9 POLYPEPTIDES, POLYNUCLEOTIDES AND USES THEREOF
EP1071707A4 (en) NEW OMEGACONOTOXIN PEPTIDE
FR2831732B1 (fr) Fourniture d'images numeriques geolocalisees personnalisees
FR2824333B1 (fr) Nouveaux polynucleotides et polypeptides de l'ifn alpha 5
NO20032963L (no) Peptidforbindelser
EP1389126A4 (en) RETROCYCLINE: ANTIVIRAL AND ANTIMICROBIAL PEPTIDES
EP1449540A4 (en) CYTOKIN INDUCING MATERAIL AND CYTOKIN INDUCTIVE INSTRUMENT
FR2760746B3 (fr) Nouveaux acylaminoacides
EP1406921A4 (en) HYPOGLYCAEMIC PEPTIDES AND METHOD FOR USE THEREOF
FR2826454B1 (fr) Cartes d'analyse
AU4587101A (en) Novel human secreted proteins and polynucleotides encoding the same
WO2002094996A8 (en) Ccl1 polynucleotides and polypeptides and uses thereof

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20110228